Internalization of [DOTA°,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radioguided surgery

Proceedings of the Association of American Physicians

Volumn 111, Issue 1, 1999, Pages 63-69

  Hofland, L J ^a   Breeman, W A P ^a   Krenning, E P ^a   De Jong, M ^a   Waaijers, M ^a   Van Koetsveld, P M ^a   Macke, H R ^a   Lamberts, S W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Endocytosis; Radioisotope guided surgery; Radiotherapy; Somatostatin analog; Uptake

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; DRUG DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; CONFERENCE PAPER; ENDOCYTOSIS; HUMAN; HUMAN CELL; INSULINOMA; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; RADIOSURGERY; RECEPTOR AFFINITY; ANIMAL; ARTICLE; CELL CULTURE; DRUG POTENTIATION; METABOLISM; RADIOASSAY; RAT;

ANIMALS; HUMANS; IODINE RADIOISOTOPES; MICE; OCTREOTIDE; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RADIOSURGERY; RATS; RECEPTORS, SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0032589981     PISSN: 1081650X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1381.1999.09110.x     Document Type: Conference Paper

References (25)

1. 1 Reubi J.C., Laissue J., Krenning E., Lamberts S.W.J. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 43: 27 35, 1992.
2. 2 Krenning E.P., Kwekkeboom D.J., Bakker W.H., et al. Somatostatin receptor scintigrpaahy with [ 111 In‐DTPA‐D‐Phe 1 ]‐ and [ 123 I‐Tyr 3 ]‐octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716 731, 1993.
3. 3 Lamberts S.W.J., Krenning E.P., Reubi J.‐C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12: 450 482, 1991.
4. 4 Krenning E.P., Kooy P.P.M., Bakker W.H., et al. Radiotherpaay with a radiolabeled somatostatin analog [ 111 In‐DTPA‐D‐Phe 1 ]‐octreotide: A case history. In: Wiedeman B., Kvols L.K., Arnold R., and Riecken E.O. (eds). Molecular and cell biological aspects of gastroenteropancreatic neuroendocrine tumor disease. Annals of the New York Academy of Sciences 733: 496 506, 1994.
5. 5 Fjälling M., Andersson P., Forsell‐Aronsson E., et al. Systemic radionuclide therpaay using indium‐111‐DTPA‐D‐Phe 1 ‐octreotide in midgut carcinoid syndrome. J. Nucl. Med. 37: 1519 1521, 1996.
6. 6 Jong de M., Bakker W.H., Krenning E.P., et al. Yttrium‐90 and indium‐111 labelling, receptor binding and biodistribution of [DOTA 0,D‐Phe 1,Tyr 3 ]octreotide, a promising somatostatin analogue for radionuclide therpaay. Eur. J. Nucl. Med. 24: 368 371, 1997.
7. 7 Schirmer W.J., O’Dorisio T.M., Schirmer T.P., et al. Intraoperative localization of neuroendocrine tumors with 125 I‐Tyr (3) ‐octreotide and a hand‐held gamma‐detecting probe. Surgery 114: 745 752, 1993.
8. 8 Wängberg B., Forssell‐Aronsson E., Tisell L.E., et al. Intraoperative detection of somatostatin‐receptor‐positive neuroendocrine tumours using indium‐111‐labelled DTPA‐D‐Phe 1 ‐octreotide. Br. J. Cancer 73: 770 775, 1996.
9. 9 Jong de M., Bernard B.F., de Bruin E., et al. Internalization of radiolabeled [DTPA 0 ]octreotide and [DOTA 0,Tyr 3 ]octreotide: Peptides for somatostatin receptor‐targeted scintigrpaahy and radionuclide therpaay. Nucl. Med. Commun. In press.
10. 10 Bakker W.H., Krenning E.P., Breeman W.A.P., et al. Receptor scintigrpaahy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity, and in vivo paaplication in animals. J. Nucl. Med. 31: 1501 1509, 1990.
11. 11 Hofland L.J., Van Koetsveld P.M., Waaijers M., et al. Internalization of the radioiodinated somatostatin analog [ 125 I‐Tyr 3 ]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide. Endocrinology 136: 3698 3706, 1995.
12. 12 Lamberts S.W.J., Hofland L.J., Van Koetsveld P.M., et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: Consequences with regard to diagnosis, localization, and therpaay. J. Clin. Endocrinol. Metab. 71: 566 574, 1990.
13. 13 Hofland L.J., Van Koetsveld P.M., Waaijers A.M., Lamberts S.W.J. Internalisation of isotope‐coupled somatostatin analogues. Digestion 57: 2 6, 1996.
14. 14 Gibson A.E., Noel R.J., Herlihy J.T., Ward W.F. Phenylarsine oxide inhibition of endocytosis: Effects on asialofetuin internalization. Am. J. Physiol. 257: C182 C184, 1989.
15. 15 Nouel D., Gaudriault G., Houle M., et al. Differential internalization of somatostatin in COS‐7 cells transfected with sst 1 and sst 2 receptor subtypes: A confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138: 296 306, 1997.
16. 16 Andersson P., Forsell‐Aronsson E., Johanson V., et al. Internalization of indium‐111 into human neuroendocrine tumor cells after incubation with indium‐111‐DTPA‐D‐Phe 1 ‐octreotide. J. Nucl. Med. 37: 2002 2006, 1996.
17. 17 Koenig J.A., Edwardson J.M., Humphrey P.P.A. Somatostatin receptors in Neuro2A neuroblastoma cells: Ligand internalization. Br. J. Pharmacol. 120: 52 59, 1997.
18. 18 Shimon I., Taylor J.E., Dong J.Z., et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. J. Clin. Invest. 99: 789 798, 1997.
19. 19 Hukovic N., Panetta R., Kumar U., Patel Y.C. Agonist‐dependent regulation of cloned human somatostatin receptor types 1–5 (hSSTR1–5): Subtype selective internalization or upregulation. Endocrinology 137: 4046 4049, 1996.
20. 20 Hipkin R.W., Friedman J., Clark R.B., et al. Agonist‐induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J. Biol. Chem. 21: 13869 13876, 1997.
21. 21 Breeman W.A.P., De Jong M., Bernard B., et al. Tissue distribution and metabolism of radioiodinated DTPA 0,D‐Tyr 1 and Tyr 3 derivatives of octreotide in rats. Anticancer Res. 18: 83 90, 1998.
22. 22 Jong de M., Bakker W.H., Breeman W.A.P., et al. Pre‐clinical comparison of [DTPA 0 ]octreotide, [DTPA 0, Tyr 3 ] octreotide and [DOTA 0,Tyr 3 ]octreotide as carriers for somatostatin receptor‐targeted scintigrpaahy and radionuclide therpaay. Int. J. Cancer 75: 406 411, 1998.
23. 23 Zamora P.O., Gulhke S., Bender H., et al. Experimental radiotherpaay of receptor‐positive human prostate adenomacarcinoma with 188 Re‐RC‐160, a directly‐radiolabeled somatostatin analogue. Int. J. Cancer 65: 214 –220, 1996.
24. 24 Stolz B., Smith‐Jones P., Albert R., et al. Somatostatin analogues for somatostatin‐receptor‐mediated radiotherpaay of cancer. Digestion 57: 17 21, 1996.
25. 25 Otte A., Mueller‐Brand J., Dellas S., et al. Yttrium‐90‐labelled somatostatin‐analogue for cancer treatment. Lancet 351: 417 418, 1998.